145 related articles for article (PubMed ID: 33116584)
41. [Roles of miR-590-5p and miR-590-3p in the development of hepatocellular carcinoma].
Yang H; Zheng W; Zhao W; Guan C; An J
Nan Fang Yi Ke Da Xue Xue Bao; 2013 Jun; 33(6):804-11. PubMed ID: 23803188
[TBL] [Abstract][Full Text] [Related]
42. LncRNA CASC9 promotes proliferation, migration and inhibits apoptosis of hepatocellular carcinoma cells by down-regulating miR-424-5p.
Yao J; Fu J; Liu Y; Qu W; Wang G; Yan Z
Ann Hepatol; 2021; 23():100297. PubMed ID: 33346094
[TBL] [Abstract][Full Text] [Related]
43. MicroRNA-424-5p acts as a potential biomarker and inhibits proliferation and invasion in hepatocellular carcinoma by targeting TRIM29.
Du H; Xu Q; Xiao S; Wu Z; Gong J; Liu C; Ren G; Wu H
Life Sci; 2019 May; 224():1-11. PubMed ID: 30876939
[TBL] [Abstract][Full Text] [Related]
44. LINC00205, a YY1-modulated lncRNA, serves as a sponge for miR-26a-5p facilitating the proliferation of hepatocellular carcinoma cells by elevating CDK6.
Cheng T; Yao Y; Zhang S; Zhang XN; Zhang AH; Yang W; Hou CZ
Eur Rev Med Pharmacol Sci; 2021 Oct; 25(20):6208-6219. PubMed ID: 34730201
[TBL] [Abstract][Full Text] [Related]
45. A c-Myc/miR-17-5p feedback loop regulates metastasis and invasion of hepatocellular carcinoma.
Liu D; Dong L; Liu Y; Wen D; Gao D; Sun H; Fan J; Wu W
Tumour Biol; 2016 Apr; 37(4):5039-47. PubMed ID: 26546431
[TBL] [Abstract][Full Text] [Related]
46. LncRNA DDX11-AS1 accelerates hepatocellular carcinoma progression via the miR-195-5p/MACC1 pathway.
Wan T; Zheng J; Yao R; Yang S; Zheng W; Zhou P
Ann Hepatol; 2021; 20():100258. PubMed ID: 32961346
[TBL] [Abstract][Full Text] [Related]
47. Cisplatin enhances NK cells immunotherapy efficacy to suppress HCC progression via altering the androgen receptor (AR)-ULBP2 signals.
Shi L; Lin H; Li G; Sun Y; Shen J; Xu J; Lin C; Yeh S; Cai X; Chang C
Cancer Lett; 2016 Apr; 373(1):45-56. PubMed ID: 26805759
[TBL] [Abstract][Full Text] [Related]
48. SNHG7 Facilitates Hepatocellular Carcinoma Occurrence by Sequestering miR-9-5p to Upregulate CNNM1 Expression.
Xie Y; Wang Y; Gong R; Lin J; Li X; Ma J; Huo L
Cancer Biother Radiopharm; 2020 Dec; 35(10):731-740. PubMed ID: 32397799
[No Abstract] [Full Text] [Related]
49. MiR-490-5p inhibits the stemness of hepatocellular carcinoma cells by targeting ECT2.
Yu Y; Cai O; Wu P; Tan S
J Cell Biochem; 2019 Jan; 120(1):967-976. PubMed ID: 30206962
[TBL] [Abstract][Full Text] [Related]
50. miR-199a-5p inhibits the proliferation of hepatocellular carcinoma cells by regulating CDC25A to induce cell cycle arrest.
Liu P; Xia P; Fu Q; Liu C; Luo Q; Cheng L; Yu P; Qin T; Zhang H
Biochem Biophys Res Commun; 2021 Sep; 571():96-103. PubMed ID: 34314996
[TBL] [Abstract][Full Text] [Related]
51. Loss of miR-192-5p initiates a hyperglycolysis and stemness positive feedback in hepatocellular carcinoma.
Gu Y; Ji F; Liu N; Zhao Y; Wei X; Hu S; Jia W; Wang XW; Budhu A; Ji J; Zhao B; Roessler S; Zheng X; Ji J
J Exp Clin Cancer Res; 2020 Nov; 39(1):268. PubMed ID: 33256802
[TBL] [Abstract][Full Text] [Related]
52. MiR-199a-5p suppresses tumorigenesis by targeting clathrin heavy chain in hepatocellular carcinoma.
Huang GH; Shan H; Li D; Zhou B; Pang PF
Cell Biochem Funct; 2017 Mar; 35(2):98-104. PubMed ID: 28261837
[TBL] [Abstract][Full Text] [Related]
53. MiR-452-5p mediates the proliferation, migration and invasion of hepatocellular carcinoma cells via targeting COLEC10.
Zheng J; Cheng D; Wu D; Wang L; Qu F; Wu X; Cheng L; Wei Y; Liu X
Per Med; 2021 Mar; 18(2):97-106. PubMed ID: 33565325
[No Abstract] [Full Text] [Related]
54. Circ-PRMT5 enhances the proliferation, migration and glycolysis of hepatoma cells by targeting miR-188-5p/HK2 axis.
Ding Z; Guo L; Deng Z; Li P
Ann Hepatol; 2020; 19(3):269-279. PubMed ID: 32089501
[TBL] [Abstract][Full Text] [Related]
55. MiR-424-5p regulates cell cycle and inhibits proliferation of hepatocellular carcinoma cells by targeting E2F7.
Zhao Y; Zhu C; Chang Q; Peng P; Yang J; Liu C; Liu Y; Chen X; Liu Y; Cheng R; Wu Y; Wu X; Hu L; Yin J
PLoS One; 2020; 15(11):e0242179. PubMed ID: 33201900
[TBL] [Abstract][Full Text] [Related]
56. Extract of
Huang X; Chen Y; Zhang X; Li F; Ye H
Cancer Biother Radiopharm; 2020 Oct; 35(8):586-595. PubMed ID: 32486841
[No Abstract] [Full Text] [Related]
57. MiR-133a-5p inhibits androgen receptor (AR)-induced proliferation in prostate cancer cells via targeting FUsed in Sarcoma (FUS) and AR.
Zheng L; Kang Y; Zhang L; Zou W
Cancer Biol Ther; 2020; 21(1):34-42. PubMed ID: 31736422
[TBL] [Abstract][Full Text] [Related]
58. CircCCNB1 silencing acting as a miR-106b-5p sponge inhibited GPM6A expression to promote HCC progression by enhancing DYNC1I1 expression and activating the AKT/ERK signaling pathway.
Liu YM; Cao Y; Zhao PS; Wu LY; Lu YM; Wang YL; Zhao JF; Liu XG
Int J Biol Sci; 2022; 18(2):637-651. PubMed ID: 35002514
[No Abstract] [Full Text] [Related]
59. Androgen receptor (AR)/miR-520f-3p/SOX9 signaling is involved in altering hepatocellular carcinoma (HCC) cell sensitivity to the Sorafenib therapy under hypoxia via increasing cancer stem cells phenotype.
Xiao Y; Sun Y; Liu G; Zhao J; Gao Y; Yeh S; Gong L; Chang C
Cancer Lett; 2019 Mar; 444():175-187. PubMed ID: 30448543
[TBL] [Abstract][Full Text] [Related]
60. The HIF-2α-MALAT1-miR-216b axis regulates multi-drug resistance of hepatocellular carcinoma cells via modulating autophagy.
Yuan P; Cao W; Zang Q; Li G; Guo X; Fan J
Biochem Biophys Res Commun; 2016 Sep; 478(3):1067-73. PubMed ID: 27524242
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
